erlotinib hydrochloride has been researched along with Ebola Hemorrhagic Fever in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bekerman, E; Einav, S | 1 |
Bakken, RR; Barouch-Bentov, R; Bekerman, E; Brannan, J; De Jonghe, S; Diamond, MS; Dye, JM; Einav, S; Govero, J; Herdewijn, P; Mateo, R; Nagamine, CM; Neveu, G; Pu, SY; Randall, G; Shulla, A; Wang, S; Xiao, F | 1 |
2 other study(ies) available for erlotinib hydrochloride and Ebola Hemorrhagic Fever
Article | Year |
---|---|
Infectious disease. Combating emerging viral threats.
Topics: Adenine; Adenosine; Antiviral Agents; Benzamides; Chloroquine; Communicable Diseases, Emerging; Cyclosporins; Cytosine; Dengue; Drug Approval; Drug Design; Erlotinib Hydrochloride; Hemorrhagic Fever, Ebola; Humans; Imatinib Mesylate; Indoles; Organophosphonates; Piperazines; Purine Nucleosides; Pyrimidines; Pyrroles; Pyrrolidines; Quinazolines; Sunitinib; Viruses | 2015 |
Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects.
Topics: Adaptor Protein Complex 1; Adaptor Protein Complex 2; Animals; Antineoplastic Agents; Antiviral Agents; Cell Line, Tumor; Dengue; Dengue Virus; Drug Evaluation, Preclinical; Drug Synergism; Ebolavirus; Erlotinib Hydrochloride; Female; Hemorrhagic Fever, Ebola; Hepacivirus; Hepatitis C; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Male; Mice, 129 Strain; Mice, Inbred C57BL; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Pyrroles; Sunitinib; Virus Internalization | 2017 |